Dr. Michael J. Lazar

Avatar

About Dr. Michael J. Lazar

Michael J. Lazar, M.D. graduated from the University of Arkansas in 1978 and completed postgraduate training in surgery and urology at LSU in 1983. He is four-time board certified by the American Board of Urology and is Managing Physician Director of Santa Rosa Surgical Management Co., LLC, which manages Santa Rosa Memorial Hospital’s Ambulatory Surgery Center. He is also Chairman of the Board of Directors of Redwood Health Services and is a member of the American Urological Association. Dr. Lazar is married with 3 children, and has been active in Boy Scout leadership and coaching soccer. His hobbies include hiking, backpacking, camping, alpine skiing, and the occasional fly-fishing outing. Dr. Lazar also enjoys living in the wine country, which affords cultivation of a love of wine, and proximity to San Francisco allows enjoyment of its theater and fine arts. Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU, a medical procedure that applies high-intensity focused ultrasound energy to locally heat and destroy diseased or damaged tissue with prostate cancer through ablation. Dr. Lazar is working closely with SonaCare to bring this innovative service to Americans with this disease.

#1 New Year’s Resolution for Men: Get screened for prostate cancer

#1 New Year’s Resolution for Men: Get screened for prostate cancer   Santa Rosa urologist and prostate cancer expert Dr. Michael Lazar provides an overview of prostate cancer screening options; says early detection saves lives. “Knowing the many options for treating prostate cancer is something all men at risk of developing the disease need to be informed about,” says Dr. Lazar. “Most men know about the unpleasant side effects that go along with traditional models of prostate cancer treatment, including urinary incontinence, bowel and erectile dysfunction. But some of the newer treatment modalities such as HIFU (high-intensity focused ultrasound) can only be undertaken at the early stages, when damage to surrounding tissue can best be mitigated, and most side effects eliminated.” Why Early [...]

2018-12-26T07:42:24-07:00December 26th, 2018|

New test may significantly enhance prostate cancer evaluation

For men newly diagnosed with prostate cancer or patients previously treated, the risk of metastasis is a crucial determinant of whether to choose conservative management or undergo further treatment. For prostate as well as other cancers, primary tumor growth or spread is driven by amplifications or deletions of portions of the genome known as copy number alterations (CNAs). A report in The Journal of Molecular Diagnostics describes a new assay to assess CNAs that is cheaper, faster, reproducible, and requires less tissue than other diagnostic techniques and has the potential to significantly enhance prostate cancer evaluation. Metastases occur in approximately 16 percent of prostate cancers and account for 8 percent of all male cancer deaths. Accurate prediction at the time of diagnosis can identify [...]

2018-12-18T08:37:55-07:00December 18th, 2018|

Study discovers link between inflammatory bowel disease and prostate cancer

. Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine. This is the first report to show men with inflammatory bowel disease have higher than average PSA (prostate-specific antigen) values, and this group also has a significantly higher risk of potentially dangerous prostate cancer. About 1 million men have inflammatory bowel disease in the U.S. Inflammatory bowel disease is a common chronic condition that includes Crohn's disease and ulcerative colitis. "These patients may need to be screened more carefully than a man without inflammatory bowel disease," said lead study author Dr. Shilajit Kundu. "If a man with inflammatory bowel disease has an elevated PSA, it may be an [...]

2018-12-11T08:37:12-07:00December 11th, 2018|

Understanding Prostate Screening & Treatment Options

For some types of cancer, screening can help find cancers at an early stage, when they are more likely to be easier to treat. According to the American Cancer Society, prostate cancer can often be found before symptoms arise by testing the amount of prostate-specific antigen (PSA) in a man’s blood. Another way to find prostate cancer is the digital rectal exam (DRE), in which the doctor puts a gloved, lubricated finger into the rectum to feel the prostate gland. If the results of either one of these tests are abnormal, further testing is often done to see if a man has cancer. If prostate cancer is found as a result of screening with the PSA test or DRE, it will probably be at [...]

2018-11-26T10:28:35-07:00November 26th, 2018|

New study looks to determine type of prostate cancer — dangerous or manageable

Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy. A recent study showed that more than 25 men were being unnecessarily treated with surgery or radiotherapy, for every single life saved. It is believed that success rates could be hindered as a result of treating all prostate cancers in the same way. A team at the University of York and the University of British Columbia, Canada, however, have designed a test that can pick out life-threatening prostate cancers, with up to 92% accuracy. Professor Norman Maitland, from the University of York's Department of Biology, said: "Unnecessary prostate treatment has both physical consequences for patients and their families, [...]

2018-11-20T07:52:53-07:00November 20th, 2018|

Scientists take step towards identifying management of prostate cancers

Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy. A recent study showed that more than 25 men were being unnecessarily treated with surgery or radiotherapy, for every single life saved. It is believed that success rates could be hindered as a result of treating all prostate cancers in the same way. A team at the University of York and the University of British Columbia, Canada, however, have designed a test that can pick out life-threatening prostate cancers, with up to 92% accuracy. Professor Norman Maitland, from the University of York's Department of Biology, said: "Unnecessary prostate treatment has both physical consequences for patients and their families, [...]

2018-11-06T07:32:36-07:00October 23rd, 2018|

Commonality found between lung and prostate cancers

UCLA researchers have discovered a common process in the development of late-stage, small cell cancers of the prostate and lung. These shared molecular mechanisms could lead to the development of drugs to treat not just prostate and lung cancers, but small cell cancers of almost any organ. The key finding: Prostate and lung cells have very different patterns of gene expression when they're healthy, but almost identical patterns when they transform into small cell cancers. The research suggests that different types of small cell tumors evolve similarly, even when they come from different organs. The study, led by Dr. Owen Witte, founding director of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and professor of microbiology, immunology and [...]

2018-10-09T09:22:01-07:00October 9th, 2018|

Scientists discover hormone therapy’s impact on prostate cancer

Scientists at Cedars-Sinai have discovered how prostate cancer can sometimes withstand and outwit a standard hormone therapy, causing the cancer to spread. Their findings also point to a simple blood test that may help doctors predict when this type of hormone therapy resistance will occur. Prostate cancer is the second-leading cause of cancer death in men, behind lung cancer, killing nearly 30,000 in the U.S. each year, according to the American Cancer Society. In its early stages, the most common type, adenocarcinoma, is curable and generally responds well to therapies, including those that target androgen -- a male sex hormone that stimulates tumor growth. However, in certain patients, the cancer becomes resistant to androgen-targeted therapy, and the cancer recurs or spreads. One possible reason [...]

2018-09-11T09:01:12-07:00September 11th, 2018|

Researchers uncover new way of targeting advanced prostate cancers

Certain molecular drivers of cancer growth are "undruggable" -- it's been nearly impossible to develop chemicals that would block their action and prevent cancer growth. Many of these molecules function by passing cancer-promoting information through a gate in the nucleus, where the instructions are carried out. Researchers at the Sidney Kimmel Cancer Center -- Jefferson Health have found a way to block the nuclear gates used by these molecules, and show that this inhibition can halt aggressive prostate cancer in mice bearing human tumors. The research, co-led by Veronica Rodriguez-Bravo, PhD, and Josep Domingo-Domenech, MD, PhD, published in Cell August 9, 2018. "We found that a particular gatekeeper, the nuclear pore protein called POM121, traffics molecules that boost tumor aggressiveness," said first and [...]

2018-08-21T07:45:39-07:00August 21st, 2018|

Eat by 9 p.m. to stave off prostate cancer say researchers

Having an early supper or leaving an interval of at least two hours before going to bed are both associated with a lower risk of breast and prostate cancer. Specifically, people who take their evening meal before 9 pm or wait at least two hours before going to sleep have an approximate 20% lower risk of those types of cancer compared to people who have supper after 10pm or those who eat and go to bed very close afterwards, respectively. These were the main conclusions of a new study by the Barcelona Institute for Global Health (ISGlobal), a center supported by the "la Caixa" Banking Foundation. The study is the first to analyses the association between cancer risk and the timing of meals and [...]

2018-08-07T11:46:52-07:00August 7th, 2018|